1 – 10 of 22
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
- Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities : further results from the prospective PANTHER study with focus on obese patients
- 2018
- A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
- 2017
-
High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer
Paulsson, J. ; Rydén, Lisa LU
; Strell, C
; Frings, O
; Tobin, Nicholas P
LU
; Fornander, T.
; Bergh, J.
; Landberg, Göran
LU
; Ståhl, O.
and Östman, A.
(2017)
In The Journal of Pathology: Clinical Research
3(1).
p.38-43
Mark
- 2015
- Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
- 2014
- Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events
- Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
- 2013
- Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel
- Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
- 2012
- Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
- 2011
-
Growth and carbon sequestration by ectomycorrhizal fungi in intensively fertilized Norway spruce forests
Wallander, Håkan LU
; Ekblad, A.
and Bergh, J.
(2011)
In Forest Ecology and Management
262(6).
p.999-1007
Mark